<code id='7ECA4B8BFE'></code><style id='7ECA4B8BFE'></style>
    • <acronym id='7ECA4B8BFE'></acronym>
      <center id='7ECA4B8BFE'><center id='7ECA4B8BFE'><tfoot id='7ECA4B8BFE'></tfoot></center><abbr id='7ECA4B8BFE'><dir id='7ECA4B8BFE'><tfoot id='7ECA4B8BFE'></tfoot><noframes id='7ECA4B8BFE'>

    • <optgroup id='7ECA4B8BFE'><strike id='7ECA4B8BFE'><sup id='7ECA4B8BFE'></sup></strike><code id='7ECA4B8BFE'></code></optgroup>
        1. <b id='7ECA4B8BFE'><label id='7ECA4B8BFE'><select id='7ECA4B8BFE'><dt id='7ECA4B8BFE'><span id='7ECA4B8BFE'></span></dt></select></label></b><u id='7ECA4B8BFE'></u>
          <i id='7ECA4B8BFE'><strike id='7ECA4B8BFE'><tt id='7ECA4B8BFE'><pre id='7ECA4B8BFE'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:9829
          Medicare is planning to send $9 billion in lump sum payments to more than 1,600 hospitals that participate in a drug discount program. Adobe

          WASHINGTON — Medicare is planning to send $9 billion in lump-sum payments to more than 1,600 hospitals that participate in a drug discount program after the Supreme Court found the program underpaid them for prescription drugs, the agency announced on Friday.

          To pay for the restitution, Medicare would slash all hospitals’ payments for other items and services by 0.5% for the next 16 years.

          advertisement

          The remedy accounts for four years of underpayments to hospitals that participate in the 340B drug discount program. The Trump administration dramatically reduced Medicare payments for discounted drugs in 2018, but the Supreme Court found they didn’t follow the proper procedure and that the payment scheme was illegal.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          3 hurdles to bringing medical devices to the U.S. market
          3 hurdles to bringing medical devices to the U.S. market

          Medicaldeviceshavehistoricallybeenseenashavingfasterpathstomarketthantheirpharmacologicalcounterpart

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          With FDA staff opposed to Sarepta therapy, top official intervened

          AlogosignoutsideoftheheadquartersofSareptaTherapeuticsinCambridge,Mass.KristofferTripplaar/SipaviaAP